Navigation Links
Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
Date:12/6/2010

The London School of Hygiene & Tropical Medicine (LSHTM) has contributed to a study showing that a low dose of aspirin reduces the occurrence of several common cancers. The study is published in today's Lancet.

The work was started and carried out by Professor Peter Rothwell in Oxford, and is based on an overview of several randomised trials of aspirin. These have been primarily concerned with reducing heart attacks, but have also gathered information on deaths from cancer.

The trial contributing most information to the overview has been the Thrombosis Prevention Trial (funded jointly by the Medical Research Council and the British Heart Foundation) which was carried out by Tom Meade when he was with the Medical Research Council. Professor Meade is now Emeritus Professor of Epidemiology in LSHTM's Department of Non-Communicable Disease Epidemiology.

As well as confirming that low dose aspirin reduces large bowel cancer cases reported in another recent study also led by Professor Rothwell and to which Professor Meade contributed, it also reduces total deaths due to cancer because it affects several common individual cancers, such as those of the oesophagus (gullet), lung, stomach, pancreas and possibly the brain. Reductions in deaths are around 20-30%.

Benefit is unrelated to aspirin dose from 75mg upwards, gender or smoking habit but increases with age. Aspirin may need to be taken for at least five years before it confers benefit, probably longer for some cancers, but benefit is generally greater the longer aspirin has been taken.

Hitherto, advice about aspirin has been mainly concerned with reducing heart attacks and strokes in those who have already had them. Caution should be exercised by those who are so far free of these conditions because, unless a person's risk of them is very high, the benefit may be outweighed by the risk of serious bleeding.

Professor Meade says: 'These are very exciting an
'/>"/>

Contact: Lindsay Wright
lindsay.wright@lshtm.ac.uk
44-794-129-4885
London School of Hygiene & Tropical Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Low-Dose Aspirin May Reduce Colon Cancer Risk
2. Low-Dose Omega-3 Fatty Acids Dont Protect Heart Patients
3. Low-Dose HRT Patch May Lessen Stroke Risk
4. Low-Dose Platelet Transfusions Deemed Safe
5. Daily Aspirin Linked to Steep Drop in Cancer Risk
6. Bleeding Risk With Plavix-Aspirin Regimen May Be Serious
7. Aspirin May Help Patients Beat Prostate Cancer
8. Aspirin, Statins May Reduce Problems After Heart Surgery
9. IV Aspirin Drip Appears to Be Safe, Effective for Migraine
10. Can aspirin prolong a healthy life?
11. Aspirin recommendations changed for many younger diabetic patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... TN (PRWEB) July 29, 2014 The ... the reimbursement model of all hospitals. Studies show that ... One simple, easy, low cost tool that great ... performance by 20 to 25%. , Their secret? Debriefing ... one anther at the end of an operational event. ...
(Date:7/29/2014)... to a more streamlined process for obtaining stem cells, which ... tissue for failing body parts, according to UC San Francisco ... Cell . , The work builds on a strategy ... in which they again have the potential to become any ... may soon increase thanks to the scientists, identification of biochemical ...
(Date:7/29/2014)... 2014 On Friday, the United States ... week of October 12-18, 2014, as "National Case Management ... improving healthcare outcomes for patients. The resolution was introduced ... (R-AR), with support by the Case Management Society of ... case management professionals for their contributions to healthcare. , ...
(Date:7/29/2014)... July 29, 2014 The Eleventh Annual ... Summit concluded with the $10,000 prize being presented to ... http://www.bikanta.com ) , The 11th Annual Summit was held ... entrepreneurs who can bring innovative products and services for ... pleased to have had such excellent array of young ...
(Date:7/29/2014)... Lean and Lovely, an affordable and short program, claims ... wear a bikini in the near future. This has caught ... , “Our Lean and Lovely review shows that ... levels. Neither your age nor your body shape matters, which ... the beginning, you will achieve the results that you have ...
Breaking Medicine News(10 mins):Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Stem cell advance may increase efficiency of tissue regeneration 2Health News:Stem cell advance may increase efficiency of tissue regeneration 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2Health News:Lean and Lovely: Review Examining Neghar Fonooni’s Program Released 2
... WASHINGTON, July 9 The Pharmaceutical Care,Management Association ... the Medicare bill, which includes a provision that ... "The inclusion of an e-prescribing requirement in ... a patient,s perspective, e-prescribing,is the most important issue ...
... Protect Patient Access To Community,Pharmacies, ALEXANDRIA, ... voted by unanimous consent in favor of ... Providers Act of 2008 contains three critical,provisions ... D claims, delayed cuts to Medicaid generic ...
... patients with the blood cancer , , WEDNESDAY, July 9 ... once-banned drug thalidomide for patients with myeloma have learned ... is to science: Don,t judge results too early. , ... increased the odds of a complete remission, but not ...
... Counseling for All Combat Veterans, WASHINGTON, July 9 ... in 39 additional,communities across the country where the Department ... 2009., "Community-based Vet Centers -- already in all ... health program," said Dr. James B. Peake,Secretary of Veterans ...
... body,s ability to repair sperm DNA, studies find , , ... over- or underweight can have a negative effect on ... to be presented July 9 at the annual conference ... in Barcelona, Spain. , While semen samples from diabetics ...
... Ind., July 9 Zimmer Holdings, Inc.,(NYSE and SWX: ... conference call will be broadcast live over the Internet ... A news release,detailing the quarterly results will be made ... The live audio webcast can be accessed via ...
Cached Medicine News:Health News:Thalidomide Continues to Show Benefits Against Myeloma 2Health News:Thalidomide Continues to Show Benefits Against Myeloma 3Health News:VA Vet Centers Coming to 39 Communities 2Health News:Diabetes, Weight Tied to Male Infertility 2
(Date:7/29/2014)... 29, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... second quarter 2014 financial results on Tuesday, August 5, ... Company,s management will hold a conference call at 8:00 ... 8:00 p.m., Beijing Time on August 6, 2014, to ...
(Date:7/29/2014)... , July 29, 2014 , ... /Oxymorphone clinical development program has commenced , ... Australia during Q4 2014 , ... States in 1H 2015 Australian drug ... on its opioid transdermal patch programs after its recent announcement of ...
(Date:7/29/2014)... ROCKLAND, Massachusetts , July 29, 2014 ... an international Phase II study investigating the efficacy and safety ... mMCC is a rare and aggressive skin cancer ... explored in a seven cohort Phase I clinical trial for ... patients  , EMD Serono, Inc., a subsidiary of ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... First Extensive Report of Bile Acid Aberration in Type 2 Diabetes ... ... N.J., June 9 /PRNewswire-FirstCall/,-- KineMed, Inc., and Daiichi Sankyo, Inc., announced ... people with type 2,diabetes which may suggest a newly identified underlying ...
... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
Cached Medicine Technology:New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 2New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 3New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 4New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 5New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 6New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 7Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: